Dylan Haversack Image

Dylan Haversack


Dylan Haversack, an associate at Rothwell Figg, is a registered patent agent, has an undergraduate degree in mechanical engineering and focuses his practice on the mechanical and electrical arts.
Prior to joining Rothwell Figg, Mr. Haversack was a summer associate at the firm where he worked on a variety of patent prosecution and litigation matters in the fields of mechanical devices, consumer products, and electrochemical systems. In this role, he gained experience working on non-final office actions and assisting in claim drafting. He also spent a summer as a patent extern at the USPTO in the Central Reexamination Unit where he conducted prior art searches and wrote office actions on reissue and re-examination applications, assisted a primary examiner on a supplemental examination, and trained and collaborated with other externs to learn patent law and patent office procedures and rules.
Mr. Haversack received his J.D. from Georgetown University Law Center where he was scholarship coordinator of the IP and Patent Law Association. He received a B.S. in mechanical engineering with highest honor from the Georgia Institute of Technology.

Recent Articles by Dylan Haversack

The mRNA IP and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)

In Part I of this three-part series, we focused on three market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss certain issues relating to lipid nanoparticle (LNP) delivery technology. Translate Bio, Inc. (NASDAQ: TBIO) is headquartered in Lexington, MA, and as of April 2021, has a market capitalization of over $1.3 billion. According to its website, Translate BIO’s mRNA product pipeline is directed to several indications including cystic fibrosis, primary ciliary dyskinesia, pulmonary arterial hypertension, COVID-19, influenza, viral pathogens, and bacterial pathogens. The company does not presently have any products on the market. However, it has one cystic fibrosis candidate and one COVID-19 vaccine candidate (with Sanofi) that are both in Phase 1/2 clinical trials. Translate BIO also appears to have one infectious disease candidate in the “IND-enabling” Phase (with Sanofi), and three lung candidates, one liver candidate, and two infectious disease candidates (with Sanofi) in the discovery phase.

The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I

Shortly after we posted about Moderna, Inc.’s October 2020 pledge not to enforce its COVID-19-related patents during the pandemic, the United States Food & Drug Administration (FDA) granted emergency regulatory approval for two COVID-19 vaccines produced by Moderna and BioNTech (with Pfizer), making these groups the first to ever enter the commercial market with mRNA-based therapies. This little-known and never-before-approved mRNA technology has since been widely administered and represents a primary weapon being used to defeat the pandemic. While this effort carries on, market players are confident that COVID-19 is but one of many indications that the mRNA technology platform might be utilized for, and that approval of the mRNA vaccines could open the door for the approval of other mRNA-based medicines, creating a wide range of new markets. With the anticipated increase in market activity and competition, we will provide an overview of the mRNA IP and competitive landscape in a series of three posts in the context of certain key players’ patent positions, drug pipelines, strategic relationships, and other attributes. These posts are based on publicly available information, are non-exhaustive, and do not identify all market players or potential market players in this space.